stockrowAllogene Therapeutics, Inc. (ALLO) vs Lyell Immunopharma, Inc. (LYEL)
- Allogene Therapeutics, Inc. ALLO 1.04 −4.59%
- Lyell Immunopharma, Inc. LYEL 14.82 −1.20%
Allogene Therapeutics, Inc. and Lyell Immunopharma, Inc. are both Biotechnology companies. Allogene Therapeutics, Inc. and Lyell Immunopharma, Inc. are of similar size ($376.6M and $367.6M). Allogene Therapeutics, Inc. grew revenue faster over the last twelve months: 7,613.1% against −63.4%. Allogene Therapeutics, Inc. has the higher net margin (−3,517.4% vs −1,701,066.7%) and the higher return on invested capital (−108.8% vs −1,070.8%). Across the 15 metrics below, Allogene Therapeutics, Inc. leads on 13 and Lyell Immunopharma, Inc. on 2.
Valuation
Profitability
| Metric | ALLO | LYEL | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 68.51% |
| Operating margin | (3,832.45%) | (1,783,580.00%) | 0.00% |
| Net margin | (3,517.41%) | (1,701,066.67%) | 0.00% |
| Free cash flow margin | (2,180.62%) | (928,333.33%) | 0.00% |
| Return on equity | (42.39%) | (97.79%) | (51.96%) |
| Return on assets | (32.43%) | (74.85%) | (46.06%) |
| Return on invested capital | (108.81%) | (1,070.83%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack